Clinical Trial Results:
Study of the preliminary efficacy and safety of topical cysteamine formulated in viscous solution in cystinosis patients
Summary
|
|
EudraCT number |
2013-003228-35 |
Trial protocol |
ES |
Global end of trial date |
23 Jul 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jul 2021
|
First version publication date |
02 Jul 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
18072013
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
VHIR
|
||
Sponsor organisation address |
Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
|
||
Public contact |
Study coordinator, VHIR, +34 934893166, nmartin@vhebron.net
|
||
Scientific contact |
Study coordinator, VHIR, +34 934893166, joaquin.lopez.soriano@vhir.org
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 Jul 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
23 Jul 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Jul 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the
study is to assess the efficacy of 0.55% cysteamine formulated in viscous solution compared with saline solution at the same dose, in corneal crystal deposition.
|
||
Protection of trial subjects |
Patients and parents were trained and informed about drop administration and possible adverse effects. Since there was no changes in the administered drug, no other measures were needed to implement.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Nov 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 5
|
||
Worldwide total number of subjects |
5
|
||
EEA total number of subjects |
5
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
2
|
||
Adolescents (12-17 years) |
3
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
- | ||||||
Pre-assignment period milestones
|
|||||||
Number of subjects started |
5 | ||||||
Number of subjects completed |
5 | ||||||
Period 1
|
|||||||
Period 1 title |
Cysteamine viscous solutions (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Viscous eyedrops | ||||||
Arm description |
Comparison of cysteamine saline solution versus viscous solution | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Mercaptamine
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Ear/eye/nasal drops, solution
|
||||||
Routes of administration |
Ophthalmic use
|
||||||
Dosage and administration details |
0.55% viscous solution of cysteamine according to previous prescription for 3 months. Followed by 0.55% viscous solution of cysteamine four times a day for 3 months
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Cysteamine viscous solutions
|
|||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Efficiency and safety of cysteamine drops
|
|||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Children with cystinosis
|
|||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Viscous eyedrops
|
||
Reporting group description |
Comparison of cysteamine saline solution versus viscous solution | ||
Subject analysis set title |
Efficiency and safety of cysteamine drops
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Children with cystinosis
|
|
|||||||
End point title |
Corneal cystine crystal deposits [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
At the end of 6 months treatment
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: 0.55% cysteamine viscous solution showed similar effects on corneal cistine crystals than saline solution. No changes were observed by modyfing frequency of instillations. Low number of enrolled patients limits the conclusions of the study. Collaboration of patients was a problem to obtain objective results |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
During the extension of the study
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||
Dictionary version |
2
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Total adverse events
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
05 Jan 2015 |
Dr Marisol Lopez Moreno was included as researcher in the study |
||
12 Jan 2015 |
Confocal microscopy was done at Hospital Clínic (barcelona) instead of Casa Maternitat because the equipment was moved |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |